Tamoxifen and ICI 182,780 interactions with thyroid hormone in the ovariectomized-thyroidectomized rat

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 1, 1997, Pages 142-148

  Dipippo, Vincent A ^a,b   Powers, C Andrew ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTRADIOL RECEPTOR; FULVESTRANT; LIOTHYRONINE; TAMOXIFEN;

ANIMAL EXPERIMENT; ARTICLE; DRUG EFFECT; DRUG RECEPTOR BINDING; FEMALE; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HORMONE RESPONSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; THYROIDECTOMY; UTERUS GROWTH;

ANIMALS; BODY WEIGHT; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; MALATE DEHYDROGENASE; ORGAN SIZE; OVARIECTOMY; RATS; RECEPTORS, ESTROGEN; RECEPTORS, THYROID HORMONE; TAMOXIFEN; THYROIDECTOMY; TRIGLYCERIDES; TRIIODOTHYRONINE; UTERUS;

EID: 0030910970     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. ARBUCKLE, N. D., DAUVOIS, S. AND PARKER, M. G.: Effects of antiestrogens on the DNA binding activity of oestrogen receptors in vitro. Nucleic Acids Res. 20: 3839-3844, 1992.
2. CAVAILLES, V., DAUVOIS, S., DANIELIAN, P. S. AND PARKER, M. G.: Interaction of proteins with transcriptionally active estrogen receptors. Proc. Natl. Acad. Sci. U.S.A. 91: 10009-10013, 1994.
3. CLARK, J. H., ANDERSON, J. H. AND PECK, E. I. J.: Estrogen receptor antiestrogen complex: atypical binding by uterine nuclei and effects on uterine growth. Steroids 22: 707-718, 1973.
4. COIRO, C., BRAVERMAN, L. E., CHRISTIANSON, D., LANG, S. AND GOODMAN, H. M.: Effect of hypothyroidism and thyroxine replacement on growth hormone in the rat. Endocrinology 105: 641-646, 1979.
5. COLOMBE, P., SCHWARTZ, H. L. AND OPPENHEIMER, J. H.: Relationship between the accumulation of pituitary growth hormone and nuclear occupancy by triiodothyronine in the rat. J. Clin. Invest. 62: 1020-1028, 1978.
6. DAUVOIS, S., DANIELIAN, P. S., WHITE, R. AND PARKER, M. G.: Antiestrogen ICI 164,383 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. SCi. U.S.A. 89: 4037-4041, 1992.
7. DICKSON, R. B. AND LIPPMAN, M. E.: Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma, Endocr. Rev. 8: 29-43, 1987.
8. DIPIPPO, V. A., LINDSAY, R. AND POWERS, C. A.: Estradiol and tamoxifen interactions with thyroid hormone in the ovariectomized-thyroidectomized rat. Endocrinology 136: 1020-1033, 1995.
9. DIPIPPO, V. A. AND POWERS, C. A.: Estrogen induction of growth hormone in the thyroidectomized rat. Endocrinology 129: 1696-1700, 1991.
10. FAWELL, S. E., WHITE, R., HOARE, S., SYDENHAM, M., PAGE, M. AND PARKER, M. G.: Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc. Natl. Acad. Sci. U.S.A. 87: 6883-6887, 1990.
11. GALLAGHER, A., CHAMBERS, T. J. AND TOBIAS, J. H.: The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats. Endocrinology 133: 2787-2791, 1993.
12. GIBSON, M. K., NEMMERS, L. A., BECKMAN, W. C., DAVIS. V. L., CURTIS, S. W. AND KORACH, K. S.: The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129: 2000-2009, 1991.
13. HALACHMI, S., MARDEN, E., MARTIN, G., MACKAY, H., ABBONDANZA, C. AND BROWN, M.: Estrogen receptor-associated proteins: possible mediators of hormoneinduced transcription. Science 264: 1455-1458, 1994.
14. INGBAR, S. H.: The thyroid gland. In Textbook of Endocrinology, ed, by J. D. Wilson and D. W. Foster, pp. 682-815, W. B. Saunders, Philadelphia, 1985.
15. JANSSON, J. O., EDEN, S. AND ISSAKSSON, O.: Sexual dimorphism in the control of growth hormone secretion. Endocr. Rev. 6: 128-150, 1985.
16. JORDAN, V. C. AND MURPHY, C. S.: Endocrine pharmacology of antiestrogens as antitumor agents. Endocr. Rev. 11: 578-610, 1990.
17. JORDAN, V. C., PHELPS, E. AND LINDGREN, J. U.: Effects of antiestrogens on bone in castrated and intact female rats, Breast Cancer Res. Treat. 10: 31-35, 1987.
18. KALU, D. N.: The ovariectomized rat model of postmenopausal bone loss. Bone Mineral 15: 175-192, 1991.
19. KATZENELLENBOGEN, B. S., BHAKOO, H. S., FERGUSON, E. R., LAN, N. C., TATEE, T., TSAI, T. S. AND KATZENELLENBOGEN, J. A.: Estrogen and antiestrogen action in reproductive tissues and tumors. Recent Prog. Horm. Res. 35: 259-300, 1979.
20. 3H-estradiol uptake in immunocytochemically characterized pituitary cells. Cell Tissue Res. 166: 25-35, 1976.
21. KOHRLE, J., HESCH, R. D. AND LEONARD, J. L.: Intracellular pathways of iodothyronine metabolism. In The Thyroid, ed. by L. E. Braverman and R. D. Utiger, pp. 144-189, J. B. Lippincott, Philadelphia. 1991.
22. KOMOLOV, I. S., PEREZ-ARCE, J. A. AND FEDOTOV, V. P.: The effects of estradiol on prolactin and growth hormone secretion in cultured pituitary cells from intact and ovariectomized rats, Endokrinologie 75: 278-284, 1980.
23. KUIPER, G. G. J. M., ENMARK, E., PELTO-HUIKKO, M., NIUHSON, S. AND GUSTAFSSON, J.-A.: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A. 93: 5925-5930, 1996.
24. LINDSAY, R., HART, D. M., FORREST, C. AND BAIRD, C.: Prevention of spinal osteoporosis in oophurectomised women. Lancet 8205: 1151-1153, 1980.
25. LOVE, R. R., WIEBE, D. A., NEWCOMB, P. A., CAMERON, L., LEVENTHAL, H., JORDAN, V. C., FEYZI, J. AND DEMETS, D. L.: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med. 10: 31-35, 1987.
26. LOVE, R. R., WIEBE, D. A., NEWCOMB, P. A., CAMERON, L., LEVENTHAL, H., JORDAN. V. C., FEYZI, J. AND DEMETS. D. L.: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann. Intern. Med. 115: 860-864, 1991.
27. MALAAB, S. A., POLLAK, M. N. AND GOODYER, C. G.: Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. Eur. J. Cancer 28A: 788-793, 1992.
28. METZGER, D., BEHRY, M., ALI, S. AND CHAMBON, P.: Effect of antagonistS on DNA binding properties of the human estrogen receptor in vitro and in vivo. Mol. Endocrinol. 9: 579-591, 1995.
29. MURPHY, L. J., MURPHY, L. C. AND FRIESEN, H. G.: Estrogen induces insulin growth factor I expression in the rat uterus, Mol. Endocrinol. 1: 445-450, 1987.
30. NABULSI, A. A., FOLSOM, A. R., WHITE, A., PATSCH, W., HEISS, G., WU, K. K. AND SZKLO, M.: Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N. Engl. J. Med. 328: 1069-1075, 1993.
31. OPPENHEIMER, J. H., SCHWARTZ, H. L., LANE, J. T. AND THOMPSON, M. P.: Functional relationship of thyroid hormone-induced lipogenesis, lipolysis, and thermogenesis in the rat. J. Clin. Invest. 87: 125-132, 1991.
32. PEAKE, G. T., BIRGE, C. A. AND DAUGHADAY, W. H.: Alterations of radioimmunoassayable growth hormone and prolactin during hypothyroidism. Endocrinology 92: 487-493, 1973.
33. POLLAK, M. N., HUYNH, H. T. AND LEFRBVRE, S. P.: Tamoxifen reduces serum insulin-like growth factor. Breast Cancer Res. Treat. 22: 91-100, 1992.
34. POWERS, C. A., HATALA, M. A. AND PAGANO, P. J.: Differential responses of pituitary kallikrein and prolactin to tamoxifen and chlorotrianisene. Mol. Cell. Endocrinol. 66: 93-100, 1989.
35. REESE, J. C. AND KATZKNELLENBOGEN, B. S.: Differential, DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: Studies using human estrogen receptor overexpressed in mammalian cells. Nucleic Acids Res. 19: 6595-6602, 1991.
36. REESE, J. C. AND KATZENELLENBOGEN, B. S.: Examination of the DNA-binding ability of estrogen receptor in whole cells: Implications for hormone-independent transactivation and the actions of antiestrogens. Mol. Cell. Biol. 12: 4531-1538, 1992.
37. ROBBINS, J.: Thyroid hormone transport proteins and the physiology of hormone binding. In The Thyroid, ed. by L. E. Braverman and R. D. Utiger, pp. 111-125, J. B. Lippincott, Philadelphia, 1991.
38. SAMUELS, H. H., FORMAN, B. M., HOROWITZ, Z. D. AND YE, Z.-S.: Regulation of gene expression by thyroid hormone. J. Clin. Invest. 81: 957-967, 1988.
39. 3H]estradiol in GRF neurons. Endocrinology 127: 344-349, 1990.
40. SIMARD, J., HURERT, J., HOSSEINZADEH, T. AND LABRIE, F.: Stimulation of growth hormone release and synthesis by estrogens in rat anterior pituitary cells in culture. Endocrinology 119: 2004-2011, 1986.
41. SITHERLAND, R., MUSTER, J. AND BAULIEU, E.: Tamoxifen is a potent 'pure' anti-oestrogen in chick oviduct, Nature 267: 434-435, 1977.
42. TURNER. R. T., RIGGS, B. L. AND SPELSBERG, T. C.: Skeletal effects of estrogen Endocr. Rev. 15: 275-300, 1994.
43. WADE, G. N., BLAUSTEIN, J. D., GRAY, J. M. AND MEREDITH, J. M.: ICI 182, 780: A pure antiestrogen that affects behaviors and energy balance in rats without acting in the brain. Am. J. Physiol. 265: R1392-R1395, 1993.
44. WADE, G. N. AND GRAY, J. M.: Gonadal effects on food intake and adiposity: A metabolic hypothesis. Physiol. Behav. 22: 583-593, 1979.
45. WADE. W. N. AND HELLER, H. W.: Tamoxifen mimics the effects of estradiol on food intake, body weight, and body composition in rats. Am. J. Physiol, 204: R1219-R1223, 1993.
46. WADE, G. N. AND SCHNEIDER, J. E.: Metabolic fuels and reproduction in female mammals. Neurosci. Biobehav. Rev. 16: 235-272, 1992.
47. WAKELING, A. E.: Use of pure antiestrogens to elucidate the mode of action of oestrogens. Biochem. Pharmacol. 49: 1545-1549, 1995.
48. WAKELING, A. E. AND BOWLER, J.: ICI 182,780, a new antiestrogen with clinical potential. J. Steroid Biochem. Mol. Biol. 43: 173-177, 1992.
49. WAKELING, A. E., DUKES, M. AND BOWLER, J.: A potent specific pure antiestrogen with clinical potential. Cancer Res. 51: 3867-3873, 1991.
50. WEBB, C. B., SZABO, M. AND FROHMAN, L. A.: Ectopic growth hormone-releasing factor and dibutyryl cyclic adenosine monophosphatE-stimulated growth hormone release in vitro: effects of corticosterone and estradiol. Endocrinology 113: 1191-1196, 1983.
51. ZHOU-LI, F., ALHALADEJO, V., JOLY-PHAHABOB, M. O., NICOLAS, B., AND ANDRE, J.: Antiestrogens prevent the stimulatory effects of L-triiodothyronine on cell proliferation. Endocrinology 130: 1145-1152, 1992.